Proportion with adverse events · patients with AD and epileptic seizures
It is very uncertain whether levetiracetam changes proportion with adverse events compared with phenobarbital (very low certainty).
1 finding from 1 review
Recurrent seizure at 12 months · children with febrile seizures
It is very uncertain whether intermittent oral levetiracetam changes recurrent seizures at 12 months compared with placebo (any antipyretics) (very low certainty).
1 finding from 1 review
Recurrent seizure at 18 months · children with febrile seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrent seizure at 24 months · children with febrile seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrent seizure at 36 months · children with febrile seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrent seizure at 48 months · children with febrile seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrent seizure at 60 months or greater · children with febrile seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrent seizure at 6 months · children with febrile seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects (cardiac) · participants with epilepsy (BECTS)
Sulthiame showed no clear difference in adverse effects (cardiac) compared with levetiracetam (low certainty).
1 finding from 1 review
Gastrointestinal adverse events · participants with epilepsy (BECTS)
Sulthiame showed no clear difference in adverse effects (gastrointestinal) compared with levetiracetam (low certainty).
1 finding from 1 review
Adverse effects (bones and muscles) · participants with epilepsy (BECTS)
Sulthiame showed no clear difference in adverse effects (bones and muscles) compared with levetiracetam (low certainty).
1 finding from 1 review
Adverse effects (others) · participants with epilepsy (BECTS)
Sulthiame showed no clear difference in adverse effects (others) compared with levetiracetam (low certainty).
1 finding from 1 review
Treatment withdrawal · participants with epilepsy (BECTS)
Sulthiame showed no clear difference in treatment withdrawal compared with levetiracetam (low certainty).
1 finding from 1 review
Seizure freedom · participants with epilepsy (BECTS)
Sulthiame showed no clear difference in seizure freedom compared with levetiracetam (low certainty).
1 finding from 1 review
Adverse effects (general symptoms) · participants with epilepsy (BECTS)
Sulthiame showed no clear difference in adverse effects (general symptoms) compared with levetiracetam (low certainty).
1 finding from 1 review
Adverse effects (central nervous system) · participants with epilepsy (BECTS)
Sulthiame showed no clear difference in adverse effects (central nervous system) compared with levetiracetam (low certainty).
1 finding from 1 review
Adverse effects (behaviour) · participants with epilepsy (BECTS)
Sulthiame showed no clear difference in adverse effects (behaviour) compared with levetiracetam (low certainty).
1 finding from 1 review
Adverse effects (airways) · participants with epilepsy (BECTS)
Sulthiame may leads to higher adverse effects (airways) compared with levetiracetam (low certainty).
1 finding from 1 review